Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Extra

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Presse Medicale (Paris, France : 1983)|July 6, 1996
[Prescription of diphosphonates in ambulatory oncology. A study of the health insurance medical services]C Vicrey, J F Bayet, J M Extra, et al.
Bulletin Du Cancer|November 1, 1993
[Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast]S Culine, J M Extra, M Espie, et al.
La Revue De Medecine Interne|May 5, 2000
[Retrospective multivariate analysis of radio-pathological correlations of nonpalpable breast lesions. Experience of the Hospital Saint-Louis]P H Cottu, I Cojean-Zelek, E Bourstyn, et al.
Journal of Hematotherapy & Stem Cell Research|January 19, 2002
Residual tumor cell contamination in peripheral blood stem cells collections of 117 breast cancer patients evaluated by immunocytochemical techniqueL Dal Cortivo, P H Cottu, J P Lotz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility studyY Merrouche, J M Extra, D Abigerges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 1999
Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experienceS Faivre, S Kalla, E Cvitkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1986
Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80)B Coiffier, P A Bryon, F Berger, et al.
Bulletin Du Cancer|January 1, 1992
[Esophageal cancer: did combined treatments improve prognosis?]G Ganem, Y Raoul, M J Goudier, et al.
British Journal of Cancer|June 1, 1994
p53 mutations and overexpression in locally advanced breast cancersA Faille, P De Cremoux, J M Extra, et al.
Cancer Research|August 15, 1994
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patientsM de Forni, R Bugat, G G Chabot, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Presse Medicale (Paris, France : 1983)|July 6, 1996
[Prescription of diphosphonates in ambulatory oncology. A study of the health insurance medical services]C Vicrey, J F Bayet, J M Extra, et al.
Bulletin Du Cancer|November 1, 1993
[Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast]S Culine, J M Extra, M Espie, et al.
La Revue De Medecine Interne|May 5, 2000
[Retrospective multivariate analysis of radio-pathological correlations of nonpalpable breast lesions. Experience of the Hospital Saint-Louis]P H Cottu, I Cojean-Zelek, E Bourstyn, et al.
Journal of Hematotherapy & Stem Cell Research|January 19, 2002
Residual tumor cell contamination in peripheral blood stem cells collections of 117 breast cancer patients evaluated by immunocytochemical techniqueL Dal Cortivo, P H Cottu, J P Lotz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility studyY Merrouche, J M Extra, D Abigerges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 1999
Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experienceS Faivre, S Kalla, E Cvitkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1986
Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80)B Coiffier, P A Bryon, F Berger, et al.
Bulletin Du Cancer|January 1, 1992
[Esophageal cancer: did combined treatments improve prognosis?]G Ganem, Y Raoul, M J Goudier, et al.
British Journal of Cancer|June 1, 1994
p53 mutations and overexpression in locally advanced breast cancersA Faille, P De Cremoux, J M Extra, et al.
Cancer Research|August 15, 1994
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patientsM de Forni, R Bugat, G G Chabot, et al.
Pageof 9